GT
AVBP icon

Glenmede Trust’s ArriVent BioPharma AVBP Stock Holding History

Glenmede Trust’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Buy
+9,061
New +$205K ﹤0.01% 1290

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Glenmede Trust's AVBP Position: Q1 2026 in Review

Glenmede Trust opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 9,061 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #1290 among its holdings.

139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Glenmede Trust held 9,061 shares of ArriVent BioPharma worth $209K as of Q1 2026.
  • ArriVent BioPharma was a new Glenmede Trust position in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #1290 holding.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.